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Osteosarcoma is classically defined as a high-grade spindle-shaped neoplasm 
with malignant cells that produce osteoid. It is the most common primary malig-
nant bone tumor in children and young adults. It is <1% of all cancers diagnosed, 
approximately 3.4% of all childhood cancers. The age-adjusted incidence of osteo-
sarcoma is bimodal, with an initial peak in adolescence and then a second peak in 
patients over 60 years of age. Osteosarcoma is divided into two main groups. In 
most of the osteosarcomas, the etiological agent cannot be determined and it is 
called primary osteosarcoma. Osteosarcoma, which develops due to etiologies such 
as Paget’s disease, radiotherapy or osteonecrosis, is called seconder osteosarcoma. 
Osteosarcomas are most commonly located in the appendicular skeleton. The most 
common settlement here is the knee circumference. The distal femur and proximal 
tibia are the most common locations in the knee. A multidisciplinary approach 
is indicated in the management of osteosarcoma. The treatment is multimodal, 
including systemic chemotherapy and local therapy. In this section, we will outline 
the current standard of care for the systemic and surgical approach to osteosarcoma 
treatment, as well as an overview of current studies.
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1. Introduction
Osteosarcoma is the most common primary malignant bone tumor. It consists of 
malignant mesenchymal cells that tend to form osteoid matter. It is defined as the 
most common bone malignant tumor after multiple myeloma and metastases [1, 2].
Three-quarters of all cases are between the ages of 10–25. The age-adjusted 
incidence of osteosarcoma is bimodal, with an initial peak in adolescence and then a 
second peak in patients over 60 years of age [3].
Osteosarcoma is most often located around the knee. Distal femur and proximal 
tibia are the most common knee localizations. The most common location after knee 
circumference is the proximal humerus. The most common location of the tumor in the 
bone is the metaphysis like many other tumors. It can rarely settle in the diaphysis [4].
2. Etiology and risk factors
In osteosarcoma cases in pediatric patients, almost all cases do not have any 
identifiable associated risk factors.
Recent Advances in Bone Tumours and Osteoarthritis
2
It has been determined that in almost half of the osteosarcoma cases seen 
in adult patients, various risk factors such as Paget’s disease and radiation are 
involved in the etiology. In addition, some syndromes such as Li Fraumeni 
Syndrome, hereditary retinoblastoma syndrome, have been reported as risk factors 
for osteosarcoma [5].
Studies have been conducted on the genetic profile of osteosarcoma in recent 
years. Studies have reported that Germline TP53 mutations may be high in osteo-
sarcomas, especially at younger ages. In osteosarcomas seen at a young age, if the 
location of the tumor is unusual, further examination is recommended in terms of 
Li-Fraumeni syndrome [6].
3. Classification
Osteosarcoma is divided into two main groups as primary and secondary osteosar-
coma. Primary osteosarcoma is divided into subtypes such as classical osteosarcoma, 
telangiectatic osteosarcoma, small cell osteosarcoma, multicentric osteosarcoma, 
high grade central osteosarcoma, low gradesurface osteosarcoma, and superficial 
(parosteal-periosteal) osteosarcoma [7].
Various etiological factors play a role in secondary osteosarcoma. Osteosarcoma 
secondary to Paget’s disease, osteosarcoma secondary to radiotherapy, osteosarcoma 
secondary to osteonecrosis, osteosarcoma secondary to fibrous dysplasia are some 
of the secondary osteosarcoma types [5].
4. Clinical findings and diagnosis
The most common clinical finding is pain and is seen in approximately 90% 
of patients. The second most common finding is swelling in the bone localization 
and is detected in approximately 50% of cases. Generally, patients present with 
complaints of pain and swelling in that area for weeks-months. Another finding 
is limitation of movement and is seen in approximately 45% of cases. In addition, 
patients rarely present with pathological fractures (about 8%) [8].
Alkaline phosphatase was found to be high in about half of osteosarcoma 
patients. High levels of lactate dehydrogenase at the time of diagnosis were found to 
be associated with relapse. In addition, Lactate dehydrogenase levels are also high in 
metastatic patients [8, 9].
In radiological evaluation, firstly, anteroposterior and lateral radiographs of 
the relevant region should be taken (Figure 1). When direct X-ray findings, bone 
involving the lesion, location of the tumor in the bone, age and gender of the 
patient are evaluated together, a correct diagnosis can be made in most of the cases 
(more than three quarters of the cases) [10].
Cortex destruction, geographic or moth-eaten-like medullary lesion, sunlight-
like periosteal reaction, Codman triangle, and soft tissue shadow in the bone 
neighborhood can be seen on plain X-ray [11].
Whenever there is any doubt about the nature of a bone lesion in a young 
patient, CT and/or MRI should be performed. Thus, new bone formation, cortical 
destruction, or soft tissue component that may indicate malignancy can be detected 
(Figure 2). In addition to imaging the primary tumor, MRI should be taken to view 
the entire bone to detect possible skip metastases [12].
Performing the MRI test before any biopsy attempt is vital, as reactive changes 
due to biopsy reduce staging accuracy [13].
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Radiological examinations are examined for the presence of findings specific 
to malignant bone tumors. These findings are sclerotic lesions that are located 
mostly in the metaphysis, progressing towards the epiphysis or diaphysis or 
laterally, radial calcified areas, disruption of the cortex integrity, fragmentation 
or elevation of the periosteum, Codman triangle and extension of the lesion to the 
soft tissue [11, 14].
The definitive diagnosis is made after the histopathological examination 
of the biopsy specimen. Biopsy should be done by the team that will make the 
definitive treatment of the patient. The formation of osteoid material and the 
presence of atypical osteoblasts are diagnostic. CT-assisted needle biopsies and, 
if necessary, incisional biopsy should be performed in the trace of the original 
surgical incision [2].
5. Staging
Osteosarcoma is considered a systemic disease. Tumor cells are present in 
the circulating blood and tumor micro-metastases are possible in the lungs. 
Approximately 10–20% of osteosarcoma patients are metastatic at the time of 
diagnosis [15].
It is a three-grade system generally used in determining tumor grade. Grade 
1 represents low grade. There is a well-differentiated tumor. Grade 2 represents 
middle grade, there is a moderately differentiated tumor. Grade 3 represents high 
grade, there is an undifferentiated tumor. If the tumor grade is low, the tumor is 
resistant to chemotherapy and radiotherapy [2, 7].
Figure 1. 
Right femur distal located osteosarcoma, a) anteroposterior and b) lateral radiography.
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Osteosarcoma most often metastasizes to the lungs. This is followed by bone 
metastases. Contrast-enhanced thin-section CT of the lung is the gold standard in 
detecting the presence of metastasis in the lung. Skip metastases in the same bone 
and distant bone metastases can be detected by Whole-Body Bone Scintigraphy. 
PET-CT is valuable in showing all body metastases and evaluating the chemotherapy 
response after treatment. Also useful for detecting nucleus [7, 8, 11].
Figure 2. 
MRI images involving the right femur distal and joint; a) coronal T1 sequence, b) coronal T2 - STIR image, c) 
axial T2 sequence and d) T1 + contrast image. In the images, the distal third of the right femur has an extension 
to the superior part of the inner femoral condyle and the midline distal of the femur, and has a satellite 
nodular structure of approximately 5.5 mm in the epiphyseal line, especially in the T1A series, the heterogeneous 
hyperintense signal in the T2A series, infiltrating bone marrow fat 12.5 there is a mass lesion of x4cm. 
Especially when T2 sequence was examined, it was determined that the mass showed extra cortical and extra 
osseous spread in the inner part, periosteal reaction and accompanying a soft tissue mass in the intramuscular 
localization with an intramuscular localization of approximately 84x48mm with a heterogeneous necrotic 
contrast in the soft tissue. Low-intensity, especially peripherally wavy rim-style contrast enhancement was 
noted in post-contrast series.
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6. Treatment management
In the past, patients with osteosarcoma were tried to be treated with amputa-
tion, but patients were lost due to micro-metastatic disease and lung metastases. 
With the discovery that chemotherapy can eliminate micro-metastases (1970’s), 
limb-sparing surgeries came to the fore [16]. The application of neoadjuvant 
chemotherapy and limb-sparing surgeries became standard in the 1980s. This 
paved the way for the development of limb salvage procedures that can achieve 
limb with better functional and cosmetic results. With the advances in treatment, 
studies on long-term functional and cosmetic extremity acquisition methods have 
increased.
With the development of induction and adjuvant chemotherapy protocols and 
advances in surgical techniques and radiological staging studies, approximately 
90–95% of patients are now treated with limb-sparing methods instead of amputa-
tion. In limb-sparing surgery, reconstruction is applied in necessary patients in 
addition to tumor resection. And after all these advances, the chance of long-term 
survival and cure rate of these patients increased to 60–80% in localized (non-
metastatic) diseases [17].
In classical osteosarcoma, the general treatment plan is preoperative (neoadju-
vant) chemotherapy, extremity conserving surgery if possible, and postoperative 
chemotherapy regimen based on the extent of tumor necrosis. In surgical treat-
ment, the tumor is resected with wide margins. Amputation is performed for 
patients who cannot undergo limb-sparing surgery [18]. Osteosarcoma is a radiore-
sistant tumor and radiotherapy does not have therapeutic properties.
The high-dose methotrexate with leucovorin rescue (HDMTX), doxorubicin and 
cisplatin (MAP) trio is the basis of standard systemic chemotherapy and is adminis-
tered for approximately 30 weeks [16]. In a newly diagnosed osteosarcoma patient, 
2 cycles of neoadjuvant chemotherapy (2 MAP cycles for approximately 10 weeks) 
are applied first.
After the HDMTX infusion administered for 2 weeks, a 1-week break is taken, 
then doxorubicin and cisplatin are administered for 2 days. And a 2-week break is 
given for bone marrow recovery. And the cycle repeats. Then, surgical treatment is 
applied [19].
Histological response value evaluated during surgical treatment is a strong 
prognostic factor. High tumor necrosis rate has better clinical outcomes after 
neoadjuvant chemotherapy [20].
The results of surgery alone are very poor in osteosarcoma treatment. And with 
chemotherapy alone, only about 10% of the patients responded [21].
Local control can be achieved through limb salvage surgery or ablative surgery 
(Figure 3). There is no significant difference between amputation and wide resec-
tion in local surgery in terms of recurrence and survival rates. Metastasectomy 
should be considered in lung metastases [14].
In recent years, many studies have been conducted on reconstruction after 
tumor resection with wide margins in local treatment and reconstruction options 
have been diversified. Custom-made or modular tumor resection prostheses are one 
of them. In addition, osteoarticular allografts and composite allografts are other 
options. With the advances in microsurgery, vascular fibula and myo-cutaneous 
flaps have also become an alternative for reconstruction. Another option is the 
method of recovered bone (reconstruction of the bone with the tumor tissue 
covered by removing the tumor, autoclaving or irradiating it or treating the bone 
with liquid nitrogen) [11, 22].
After the HDMTX infusion administered for 2 weeks, a 1-week break is given, 
then doxorubicin and cisplatin are administered for 2 days. And a 2-week break is 
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given for bone marrow recovery. And the cycle repeats. Then, surgical treatment 
is applied [16].
Overall survival for lower limb reconstructions ranges from about 70–85% at 
5 years [23].
Adjuvant MAP therapy should be initiated within 3 weeks after surgical treat-
ment. Because especially in patients with low tumor necrosis rate, a delay of more 
than 3 weeks is associated with high recurrence rates. Current standard adjuvant 
chemotherapy includes a total of 29 weeks of MAP cycles.
7. Prognosis
Several prognostic factors have been identified in the management and follow-
up of osteosarcoma. Stage (local-systemic spread) is a poor prognostic factor. As 
the tumor stage increases, the prognosis worsens. Another prognostic factor is 
tumor grade. Low grade types are parosteal osteosarcoma, periosteal osteosarcoma 
and low-grade intramedullary osteosarcoma. Tumor size is poor prognostic. As 
the tumor size increases, the prognosis worsens. Tumor localization affects the 
prognosis. Tumors located distal to the elbow in the upper extremity and tumors 
located distal to the knee in the lower extremity have a relatively better prognosis. 
It has been reported that the presence of pathological fractures does not affect the 
prognosis. Gender has also been reported as a prognostic factor. The prognosis is 
Figure 3. 
Right femur distal located osteosarcoma, post-operatively a) anteroposterior and b) lateral radiography. There 
was skip metastasis in the epiphysis localization of the distal femur. Tumor resection with white margins and 
reconstruction operation with distal femur tumor resection prosthesis were performed as local treatment.
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relatively better in female patients. Prognosis is worse in secondary osteosarcoma. 
Five-year survival is less than 10% in osteosarcoma patients developing on the basis 
of Paget’s disease, and 5-year survival is less than 20% in patients with osteosar-
coma developing on a radiation background [11, 14, 24]. The presence of metastatic 
disease is another poor prognostic factor.
Patients should be followed for at least five years in terms of systemic metastases 
postoperatively.
In patients with macro-metastasis at the time of diagnosis, despite systemic 
chemotherapy and surgery, 5-year disease-free survival is approximately 20% [25]. 
In addition, 10-year survival is less than 20% in relapse cases [26].
8. Recent advances
Studies on intensified chemotherapy are continuing in patients who underwent 
surgery after neoadjuvant chemotherapy and in patients with poor histological 
response detected during surgery. Poor histological responders are defined as 
patients who maintain more than 10% viable tumors following surgery. Current 
studies report that chemotherapy intensification has less successful results than 
thought [20, 27].
Several clinical studies have been investigating the intensification of adjuvant 
chemotherapy by adding high-dose ifosfamide with or without etoposide to MAP 
for poor histological responders following definitive surgery. However, it has not 
been shown to be superior to standard chemotherapy. In addition, studies with 
cytokine interferon alfa-2b showed that this agent did not provide superiority to 
standard therapy [20, 27].
Studies with high-dose ifosfamide to avoid the long-term nephrotoxic effects of 
methotrexate have shown equivalent effect rates [28]. Similarly, studies have been con-
ducted with dexrazoxane to avoid long-term nephrotoxic effects of doxorubicin. [29].
9. Conclusions
The current standard of care for a patient with newly diagnosed osteosarcoma 
includes 2 cycles of MAP neoadjuvant chemotherapy followed by local tumor sur-
gery and 29 weeks of adjuvant MAP chemotherapy. With this standard approach, 
disease-free survival is approximately 70% in patients with localized disease at the 
time of diagnosis.
Treatment outcomes for patients with osteosarcoma, for localized, metastatic, or 
relapse patients, have not improved significantly and have not gotten better in the 
last 10 years, despite many improvements and extensive studies.
The poor results of patients with low necrosis during surgery after neoadjuvant 
chemotherapy still appear as a treatment challenge. It has been shown that intensi-
fied chemotherapy methods, which have been emphasized in recent years, are not 
superior to conventional treatment. It is clear that more work is needed.
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